Triton Agreement and Precision Study

Inclusion Criteria for Normal Group 1. Subjects 18 years of age or older on the date of informed consent 2. Subjects able to understand the written informed consent and willing to participate as evidenced by signing the informed consent 3. Subjects presenting at the site with normal eyes bilaterally (cataracts are acceptable) 4. IOP ≤ 21 mmHg bilaterally 5. BCVA 20/40 or better bilaterally Exclusion Criteria for Normal Group 1. Subjects unable to tolerate ophthalmic imaging 2. Subjects with ocular media not sufficiently clear to obtain acceptable OCT images 3. HFA visual field (24-2 Sita Standard, white on white) result unreliable (based on manufacturer's recommendation), defined as fixation losses \> 20% or false positives \> 33%, or false negatives \> 33% 4. Visual field defects consistent with glaucomatous optic nerve damage based on at least one of the following two findings: 1. On pattern deviation (PD), there exists a cluster of 3 or more points in an expected location of the visual field depressed below the 5% level, at least 1 of which is depressed below the 1% level; 2. Glaucoma hemi-field test "outside normal limits." 5. Narrow angle 6. History of leukemia, dementia or multiple sclerosis 7. Concomitant use of hydroxychloroquine and chloroquine Inclusion Criteria for Glaucoma Group 1. Subjects 18 years of age or older on the date of informed consent 2. Subjects able to understand the written informed consent and willing to participate as evidenced by signing the informed consent 3. BCVA 20/40 or better in the study eye 4. Visual field defects consistent with glaucomatous optic nerve damage based on at least one of the following two findings: 1. On pattern deviation (PD), there exists a cluster of 3 or more points in an expected location of the visual field depressed below the 5% level, at least 1 of which is depressed below the 1% level; 2. Glaucoma hemi-field test "outside normal limits." 5. Glaucomatous optic nerve damage as evidenced by any of the following optic disc or retinal nerve fiber layer structural abnormalities: 1. Diffuse thinning, focal narrowing, or notching of the optic disc rim, especially at the inferior or superior poles with or without disc hemorrhage; 2. Localized abnormalities of the peripapillary retinal nerve fiber layer, especially at the inferior or superior poles; or 3. Optic disc neural rim asymmetry of the two eyes consistent with loss of neural tissue Exclusion Criteria for Glaucoma Group 1. Subjects unable to tolerate ophthalmic imaging 2. Subject with ocular media not sufficiently clear to obtain acceptable OCT images 3. HFA visual field (24-2 Sita Standard, white on white) result unreliable, defined as fixation losses \> 20% or false positives \> 33%, or false negatives \> 33% in the study eye 4. Presence of any ocular pathology except glaucoma in the study eye (cataracts are acceptable) 5. History of leukemia, dementia or multiple sclerosis 6. Concomitant use of hydroxychloroquine and chloroquine Inclusion Criteria for Retina Disease Group 1. Subjects 18 years of age or older on the date of informed consent 2. Subjects able to understand the written informed consent and willing to participate as evidenced by signing the informed consent 3. Subjects presenting at the site with retinal disease 4. IOP ≤ 21 mmHg in the study eye 5. BCVA 20/400 or better in the study eye 6. Diagnosis of some type of retinal pathology by investigator, may include, but not limited to: Macular Degeneration, Diabetic Macular Edema, Diabetic Retinopathy, Macular Hole, Epiretinal Membrane, Cystoid Macula Edema, and others Exclusion Criteria for Retinal Disease Group 1. Subjects unable to tolerate ophthalmic imaging 2. Subject with ocular media not sufficiently clear to obtain acceptable OCT images 3. Presence of glaucoma or any ocular pathology other than a Retinal pathology (e.g., cornea pathology) in the study eye (cataracts are acceptable) 4. Narrow angle in the study eye 5. History of leukemia, dementia or multiple sclerosis 6. Concomitant use of hydroxychloroquine and chloroquine